Abbreviations: ASA, aryl sulfatase A; BSA, bovine serum albumin; CSAct, cerebroside sulfate activator protein; Da, dalton (one twelfth the mass of carbon-12); ESI, electrospray ionization mass spectrometry; IS, internal standard; MALDI, matrix assisted laser desorption ionization mass spectrometry; MLD, metachromatic leukodystrophy; MRM, multiple reaction monitoring; MS/MS, tandem mass spectrometry; TOF, time-of-flight; U, unit of enzyme activity (the amount of enzyme activity which will catalyze the transformation of 1 μmole of the substrate per minute under standard conditions).
Introduction
Metachromatic Leukodystrophy (MLD) is a neurodegenerative autosomal recessive disease in which affected individuals most commonly have a defect in arylsulfatase A (ASA) enzyme activity originating from approximately sixty different known mutations (1) . MLD can also arise as a result of a defective cerebroside-sulfate activator protein (CSAct), also known as saposin B (2), or as the sphingolipid activator protein 1 (SAP-1) (3) or as the non-specific activator protein (4) . In this and other publications from the UCLA group, this protein is referred to as CSAct to reflect the activity that is measured. The function of ASA is to metabolize intracellular sulfatide (sulfogalactosyl cerebroside) via enzymatic hydrolysis of the 3-O-galactosyl-sulfate group. However, ASA is apparently unable to perform this function as long as the lipid substrate is confined within the membrane. CSAct is thought to sequester sulfatide from membrane fragments incorporated into lysosomes by a poorly understood lipid exchange mechanism (5) , and in the resulting CSAct-sulfatide complex the polar sugar sulfate moiety is sufficiently exposed for hydrolysis catalyzed by lysosomal ASA (Figure 1 ). During this process the hydrophobic tail of the lipid is confined to a pocket within the dimeric protein shell and is shielded from the hydrophilic environment (6) . Thus, the true in vivo substrate for ASA is the CSAct-sulfatide complex, and in this process CSAct serves as the lipid carrier Humans deficient in ASA and/or CSAct activity are unable to catabolize sulfatide leading to sulfatide accumulation and subsequently neurological damage (7) . In MLD affected individuals, progressive demyelination of central and peripheral axonal myelin sheaths occurs via an unclear mechanism. This results in various debilitating clinical symptoms including loss of previously achieved milestones in infants such as walking, crawling and chewing, along with symptoms of hypotonia, hyporeflexia, optic atrophy, and eventually death.
In principle, both CSAct and ASA activity could be measured in vitro by measuring the temporal change in concentration of one or more of the participating reactants/products in the coupled reaction ( Figure 1 ). This would involve measuring the rates of either substrate (sulfatide) depletion, or product (cerebroside and/or inorganic sulfate) formation. In practice, ASA activity can be measured using artificial substrates (p-nitrocatechol sulfate or 4-methylumbelliferyl sulfate) by following the formation of colored (pnitrocatechol, λ max 550 nm, 8) or fluorescent (4-methylumbelliferol, λ ex 365, λ em 450 nm, 9) products, respectively. These assays are performed without difficulty in a homogeneous milieu because all by guest, on www.jlr.org Downloaded from participants in the reaction are water-soluble. However, assays using natural sulfatide substrate are more complicated because of the poor water solubility of monomeric sulfatide and its propensity to form aggregates. In this case ASA activity can be measured using detergent-solubilized sulfatide (10) , while CSAct activity can be measured using CSAct-solubilized sulfatide (11) . As previously done in the UCLA laboratory, both these procedures involve measuring the rate of inorganic sulfate formation.
Since existing assays for inorganic sulfate were insufficiently sensitive, 35 S-radiolabeled sulfatide was used and the production of radioactive inorganic sulfate measured. 35 S-Radiolabeled sulfatide is prepared by in vivo administration of 35 S-sulfate to rat pups, followed by extraction and purification of the radiolabeled lipid (12) . This radiolabeled lipid is not available commercially and the tedious and time-consuming preparation requires relatively large amounts of radioactivity to yield a product with adequate specific activity. Furthermore, the short 35 There is a need for a more convenient assay with which the natural substrate system can be monitored.
Mass spectrometry provides a valuable tool for the analysis of lipids and lipid metabolizing enzymes (13) . Previous work employing mass spectrometry for the analysis of lipid metabolizing enzymes has involved the use of matrix assisted laser desorbtion ionization (MALDI) and electrospray ionization mass spectrometry (ESI, 14, 15) . In the present case the possibility of following sulfatide depletion by ESI has been tested by taking advantage of the strong signals these lipids yield in the negative ion mode (16, 17) , while more importantly the possibility of following cerebroside formation has been tested by taking advantage of the strong signals that these lipids yield as their lithiated adducts in the positive ion mode (18) . These two approaches have been tried and here we present the results of this comparison which showed that monitoring cerebroside formation by ESI coupled to tandem mass spectrometry (MS/MS) provides a reliable, fast, specific, non-radioactive method for assays involving both CSActand detergent-solubilized sulfatide. The assays have been used to reveal hitherto obscure but potentially important details of the sulfatide specificity for binding by CSAct, and saposin specificity for the ASA catalyzed reaction.
Materials and Methods:
Chemicals Preparation of synthetic sulfatides. Non-hydroxylated sulfatides with fatty acyl chain (R moiety, Figure   1 ) compositions of C 16 :0 (palmitic), C 18 :0 (stearic), C 22 :0 (behenic) and C 24 :1 15 (nervonic), were synthesized as described (19) . Hydroxylated sulfatides with fatty acyl chain (R moiety, Figure 1) compositions of α-hydroxylated C 18 :0 (hC 18 :0, α-hydroxy-stearic) and hC 22 (85/15, v/v), the galactosylceramide was selectively sulfated at position 3 as previously described (19) and the 3-O-sulfated products were recovered in 50% yields. ASA: ASA was purified from human liver as previously described (22) and stored at -80 o C in 25 mM
Tris-Cl at pH 7.5 with a specific activity of about 3000 U/mg protein as determined by a modified Baum (8) assay using p-nitrocatechol sulfate as substrate. When needed for the CSAct and ASA assays, the stock was diluted in 25mM Tris-HCl, pH 7.5 containing 1 mg/mL BSA to an activity of 250 U/mL.
CSAct and saposins A, C and D:
Native CSAct was purified from pig kidney as previously described (11) . The preparation contained predominantly a glycosylated 79-amino acid residue protein and has been extensively characterized by chromatographic and mass spectrometric analysis (23) The stock solutions were diluted in 25 mM Tris-HCl buffer (pH 7.5) for use in the CSAct assay.
The other set of non-glycosylated human recombinant proteins were produced by the Toronto group without any purification tags in a thioredoxin reductase deficient strain of E. coli and purified by heat treatment followed by sequential ion-exchange, gel filtration and hydrophobic interaction chromatography using a previously described system (28) . The final preparations were stored as 7. Data Processing: Representative spectra were computed as the average of all the spectra accrued from each injection using instrument-supplied software (MacSpec™, version 3.3, PE Sciex, Ontario, Canada).
MRM profiles were smoothed and peak areas determined using the IGOR Pro™ software package (version 3, WaveMetrics, Inc., Lake Oswego, OR) and converted to moles of cerebroside using the response from the IS. Reaction rates were expressed as moles of product/hour/mg of saposin.
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Results and Discussion
As previously reported the negative ion ESI spectra of brain sulfatide reveal a series of ions from m/z 806 to 950 reflecting the relative abundance of the various species of this lipid in the brain ( Figure 4A ; 16, 17) . The positive ion spectra of brain cerebrosides in the presence of lithium (18) Figure 6 ). There was no detectable formation of cerebroside in the absence of added CSAct. The limitation of data accumulation to eight separate MRM transitions is a consequence of the data system used for this work, and with contemporary systems this could be expanded to include the less abundant cerebrosides, should that be necessary. A refinement to the procedure would be IS addition at the end of the incubation rather than immediately prior to mass spectrometry. A further refinement would be the use of a specific IS for each cerebroside monitored.
However, at the moment only 2 H 35 -C 18 :0 cerebroside is commercially available. Nevertheless, the specific activity for the data represented in Figure 6 for the combined seven most abundant cerebroside species in the assay is 579.2 nmols cerebroside formed/hour/mg CSAct, which is in good agreement with data from the radioactive-based assay that varies around 600 nmols of sulfate formed/hour/mg CSAct, when run under similar conditions (11, 24, 31) .
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In the MRM assay it is possible to individually monitor the saturated (C 18 :0, C 22 :0, and C 24 :0) as well as the hydroxylated-saturated (hC 18 :0 and hC 24 :0) and the mono-unsaturated cerebrosides (C 24 :1, and C 26 :1) in the presence of the IS. This allowed a comparison of the specific activity for each cerebroside, which is impossible with the radioactive based methodology. Notable differences in specific activity were found among the seven cerebrosides analyzed (Figure 7) . However, the bovine brain sulfatide substrate is a mixture of more than ten different species (17) in varying relative abundance. Therefore the differences observed in the rate of formation of the various cerebrosides could arise either as a consequence of differential substrate preference and/or abundance. In order to address this question the data was re-expressed relative to the abundance of the corresponding substrate species. The activity profile then showed no significant differences between the individual species, with the exception that the The interaction between CSAct and lipids has been previously evaluated by several different paradigms.
Exchange between bound and unbound lipids can be observed under acidic conditions, but at neutral pH the CSAct-lipid complex is stable and can be isolated free of unbound ligand by several techniques including size exclusion chromatography, gel electrophoresis and thin layer chromatography (32) (33) (34) .
These in vitro studies have shown that CSAct binds a varied but limited repertoire of lipids in addition to sulfatide, including gangliosides (G D3 and G m1 ), phosphoinositols (tri-, di-and mono-phosphates), globosides (Gb 3 and Gb 4 ), sphingomyelin and cerberoside in addition to some other lipids (35) . It appears from these studies that ligands with longer and/or more complex lipoidal and polar components are favored. However, any preference of CSAct for any one of the many naturally occurring sulfatide molecular species has never been previously investigated. This is because homogeneous preparations of the individual sulfatide species have not been previously available, and because it is impossible to study such preferences with a heterogeneous substrate and the radioactivity-based assay. In this new mass However, caution should be exercised when extrapolating to the in vivo situation since the in vitro assay does not exactly reflect the catabolic situation of sulfatides within the lysosomal compartment. The assay presents the sulfatide substrates in a micellar form in the absence of any other membrane lipids.
In the lysosomal compartment, sulfatide substrates are presumably presented as components of inner lysosomal membranes rich in bis(monoacylglycero)phosphate. This lipid is specific for the inner membranes and stimulates sphingolipid hydrolysis. The topology of lysosomal digestion (38) may affect the specificity of the CSAct and arylsulfatase A, and especially their variants present in patients, in a different way than in the micellar situation used in the in vitro assay.
In order to adapt the system for the study of ASA rather than the CSAct, the detergent based assay was run using the MRM method, and the limits for detection of enzymatic activity were assessed. It was found that the presence of the detergent taurodeoxycholate at up to 5 mg/mL and 0.12 M NaCl in the reaction mixture did not interfere with the ability to assay the enzyme. Assaying ASA under these conditions using between 0.025 -0.0025 U/tube gave linear increases in cerebroside formation during incubation times between 0-90 minutes. It was concluded the assay had a limit of detection for ASA of around 0.0025 U/tube. The taurodeoxycholate-based assay is used clinically to assess potential defects in ASA activity and as such has significant diagnostic importance for the evaluation of MLD. The development of an MRM-based procedure that avoids the need for radiolabeled substrate could find clinical utility.
Finally it should be noted that earlier efforts focused on using the strong negative ESI signals obtained We have developed a mass spectrometric method for assaying the coupled ASA/CSAct reaction that provides information on the rate of formation of specific cerebroside products, thus allowing a more 
4.

5.
6.
7.
8.
CSAct per reaction tube (mg) Figure 6 . 
